

Morton Coleman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6470836/publications.pdf>

Version: 2024-02-01

118
papers

2,579
citations

430874

18
h-index

197818

49
g-index

118
all docs

118
docs citations

118
times ranked

3058
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2364-2373.	3.5	53
2	Involved-site radiotherapy for <i>Helicobacter pylori</i> -independent gastric MALT lymphoma: 26 years of experience with 178 patients. <i>Blood Advances</i> , 2021, 5, 1830-1836.	5.2	17
3	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	6.2	14
4	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	7.0	42
5	Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 1554-1562.	4.1	1
6	Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 812-812.	1.4	7
7	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	5.2	67
8	Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance. <i>Blood</i> , 2020, 136, 24-25.	1.4	3
9	MAGNIFY phase IIIb interim analysis of induction R ² followed by maintenance in relapsed/refractory indolent NHL. <i>Journal of Clinical Oncology</i> , 2020, 38, 8046-8046.	1.6	10
10	Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 30-31.	1.4	1
11	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2027-2038.	2.4	20
12	Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 539-545.	4.1	4
13	Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2019, 3, 603-611.	5.2	10
14	Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial. <i>Blood</i> , 2019, 134, 694-694.	1.4	4
15	Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). <i>Journal of Clinical Oncology</i> , 2019, 37, 7530-7530.	1.6	9
16	Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution. <i>Blood</i> , 2019, 134, 5644-5644.	1.4	0
17	Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4399-4399.	1.4	0
18	An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 400-407.e1.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. <i>Annals of Diagnostic Pathology</i> , 2018, 37, 57-61.	1.3	3
20	Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4144-4144.	1.4	5
21	Response rate to lenalidomide plus rituximab (R ²) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIb study of R2 followed by maintenance in relapsed/refractory indolent NHL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7516-7516.	1.6	6
22	Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL). <i>Journal of Clinical Oncology</i> , 2018, 36, 7549-7549.	1.6	15
23	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 930-937.	2.0	10
24	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	1.4	243
25	Oral Lymphomatoid papulosis type C: A diagnostic pitfall, often confused with T-cell lymphoma. <i>Annals of Diagnostic Pathology</i> , 2017, 31, 50-55.	1.3	8
26	Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2017, 4, e24-e34.	4.6	33
27	Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 825-833.	0.4	7
28	Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102). <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7578-TPS7578.	1.6	1
29	Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202). <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7579-TPS7579.	1.6	2
30	CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 127, 3360-3368.	1.4	89
31	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. <i>Oncotarget</i> , 2016, 7, 4598-4610.	1.8	53
32	Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 3065-3070.	1.3	20
33	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , 2015, 125, 2497-2506.	1.4	618
34	Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2870-2875.	1.3	15
35	Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib. <i>Blood</i> , 2015, 126, 4232-4232.	1.4	4
36	High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma. <i>Blood</i> , 2015, 126, 4258-4258.	1.4	5

#	ARTICLE	IF	CITATIONS
37	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. <i>Blood</i> , 2015, 126, 703-703.	1.4	4
38	Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma. <i>Blood</i> , 2015, 126, 2991-2991.	1.4	1
39	Higher BTK-Dependent Cell Proliferation in Unmutated Chronic Lymphocytic Leukemia Confers Increased Sensitivity to Ibrutinib. <i>Blood</i> , 2015, 126, 5296-5296.	1.4	0
40	Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation. <i>Blood</i> , 2015, 126, 500-500.	1.4	7
41	An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma. <i>Blood</i> , 2015, 126, 3027-3027.	1.4	0
42	Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 517-524.	0.8	18
43	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 48-58.	10.7	438
44	Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 107-113.	0.4	14
45	The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant Waldenström's Macroglobulinemia. <i>Blood</i> , 2014, 124, 1689-1689.	1.4	5
46	Acquired in Vitro Resistance to Ibrutinib Is Associated with Transcriptional Re-Programming and Sustained Survival Signaling in Waldenström's Macroglobulinemia and Mantle Cell Lymphoma, Independent of BTK Cys481 Mutation. <i>Blood</i> , 2014, 124, 2250-2250.	1.4	3
47	Therapeutic Sensitivity of CD20- Waldenström's Macroglobulinemia Cells Is Determined By Underlying Genomic and Epigenetic Events. <i>Blood</i> , 2014, 124, 3115-3115.	1.4	3
48	Targeted Disruption of USP14 and UCHL5 with the Novel Deubiquitinase Enzyme (DUB) Inhibitor, VLX1570, Induces Immense Proteotoxicity and Cell Death in Malignant Plasma Cells. <i>Blood</i> , 2014, 124, 3116-3116.	1.4	3
49	Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4754-4754.	1.4	5
50	Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 4761-4761.	1.4	1
51	Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report. <i>Blood</i> , 2014, 124, 625-625.	1.4	9
52	The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 2016-2016.	1.4	1
53	Methylation Patterns in Waldenström's Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and Cepba Family of Transcription Factors. <i>Blood</i> , 2014, 124, 3551-3551.	1.4	2
54	Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone). <i>Blood</i> , 2014, 124, 5778-5778.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Inhibition Of The Deubiquitinating Enzymes UCHL5 and USP14 Is Lethal To Waldenström's Macroglobulinemia Cells. <i>Blood</i> , 2013, 122, 1823-1823.	1.4	2
56	Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 1954-1954.	1.4	7
57	Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 1955-1955.	1.4	6
58	Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3216-3216.	1.4	3
59	The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial. <i>Blood</i> , 2013, 122, 4393-4393.	1.4	5
60	A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL. <i>Blood</i> , 2013, 122, 4914-4914.	1.4	3
61	Interim FDG PET/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8555-8555.	1.6	3
62	The Deubiquitinating Enzymes Of The 19S Proteasome Offer Novel Therapeutic Opportunity In Bortezomib Resistant Waldenström's Macroglobulinemia. <i>Blood</i> , 2013, 122, 4426-4426.	1.4	0
63	Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. <i>Hematology</i> , 2012, 17, s90-s92.	1.5	14
64	Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL. <i>Blood</i> , 2012, 120, 3706-3706.	1.4	2
65	ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 77-77.	1.4	11
66	Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8036-8036.	1.6	4
67	Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).. <i>Journal of Clinical Oncology</i> , 2012, 30, e21006-e21006.	1.6	0
68	Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy. <i>Blood</i> , 2012, 120, 1636-1636.	1.4	1
69	BTK Inhibition Targets in Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity.. <i>Blood</i> , 2012, 120, 2903-2903.	1.4	3
70	Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population. <i>Blood</i> , 2012, 120, 4269-4269.	1.4	0
71	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Blood</i> , 2011, 118, 2042-2042.	1.4	1
72	A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,. <i>Blood</i> , 2011, 118, 3701-3701.	1.4	13

#	ARTICLE	IF	CITATIONS
73	Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy.. Blood, 2011, 118, 3712-3712.	1.4	1
74	ClaPD (Clarithromycin/[Biaxin [®]], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. Blood, 2011, 118, 635-635.	1.4	10
75	T-Bird (thalidomide, clarithromycin/[Biaxin [®]], lenalidomide/[Revlimid [®]], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma. Blood, 2011, 118, 2937-2937.	1.4	0
76	Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.. Blood, 2010, 116, 1785-1785.	1.4	1
77	A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.. Blood, 2010, 116, 1795-1795.	1.4	9
78	A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil [®]) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide. Blood, 2010, 116, 2258-2258.	1.4	1
79	Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin [®]], lenalidomide/[Revlimid [®]],) Tj ETQq1 1 0.784314 rgBT /Overlock 10T	1.4	0
80	MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells. Blood, 2010, 116, 785-785.	1.4	1
81	Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities. Blood, 2010, 116, 3561-3561.	1.4	1
82	Lenalidomide in renal insufficiency â€“ balancing the risks and benefits: response to Borrello. British Journal of Haematology, 2009, 144, 447-448.	2.5	2
83	A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.. Blood, 2009, 114, 1877-1877.	1.4	5
84	CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).. Blood, 2009, 114, 2682-2682.	1.4	4
85	ZAP-70 Expression Assessed by Immunohistochemistry Correlates with Time to First Treatment in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 4686-4686.	1.4	0
86	At-101 Induces Apoptosis WaldenstroÌm Macroglobulinemia Cells Resistant to Bortezomib.. Blood, 2009, 114, 2861-2861.	1.4	8
87	The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.. Blood, 2009, 114, 4349-4349.	1.4	0
88	Levels of Circulating Endothelial Cells and Endothelial Progenitors Correlate with Disease Status and Treatment Response in Human Lymphoma Subtypes of CLL and MCL.. Blood, 2009, 114, 3941-3941.	1.4	0
89	Activity of SYK and PLCÎ²2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib.. Blood, 2009, 114, 1249-1249.	1.4	0
90	Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.. Blood, 2009, 114, 2311-2311.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Prednisone, etoposide, procarbazine, and cyclophosphamide (PEPâ€ƒ) oral combination chemotherapy regimen for recurring/refractory lymphoma: Lowâ€ƒdose metronomic, multidrug therapy. <i>Cancer</i> , 2008, 112, 2228-2232.	4.1	57
92	Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 447-450.	1.3	38
93	Targeting Early Events of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Suppressed Syk and PLCÎ² Activities Predict Apoptotic Response of Leukemic Cells to Dasatinib. <i>Blood</i> , 2008, 112, 5023-5023.	1.4	0
94	Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2007, 110, 3024-3024.	1.4	1
95	Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.. <i>Blood</i> , 2007, 110, 2737-2737.	1.4	1
96	Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas. <i>Cancer</i> , 2006, 107, 1425-1428.	4.1	14
97	Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2751-2751.	1.4	7
98	Stromal Incorporation of VEGFR-1+, CD68+ and Î±-SMA+ Hemangiogenic Cells Correlates with Histologic Subtype in Non-Hodgkinâ€™s Lymphoma.. <i>Blood</i> , 2005, 106, 1930-1930.	1.4	1
99	Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2005, 106, 2574-2574.	1.4	8
100	Thalidomide Is Active Alone and in Combination with Fludarabine in Fludarabine-Relapsed and Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 4835-4835.	1.4	1
101	Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.. <i>Blood</i> , 2004, 104, 1497-1497.	1.4	0
102	Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. <i>Seminars in Oncology</i> , 2003, 30, 270-274.	2.2	56
103	Epratuzumab: targeting B-cell malignancies through CD22. <i>Clinical Cancer Research</i> , 2003, 9, 3991S-4S.	7.0	34
104	Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. <i>Cancer</i> , 2002, 94, 879-888.	4.1	187
105	Comparison of fluorineâ€ƒ18 fluorodeoxyglucose positron emission tomography and Gaâ€ƒ67 scintigraphy in evaluation of lymphoma. <i>Cancer</i> , 2002, 94, 879-888.	4.1	8
106	Primary Non-Hodgkin's Lymphoma of Bone. <i>Cancer Investigation</i> , 1998, 16, 616-617.	1.3	0
107	Ki-1 Skin Lymphoproliferative Disorders: Management with Radiation Therapy. <i>Cancer Investigation</i> , 1997, 15, 91-97.	1.3	10
108	Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). <i>International Journal of Cancer</i> , 1988, 41, 829-831.	5.1	4

#	ARTICLE	IF	CITATIONS
109	An association between chronic neutrophilic leukaemia and multiple myeloma with a study of cobalamin-binding proteins. <i>British Journal of Haematology</i> , 1986, 63, 173-180.	2.5	30
110	HAC-cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. <i>Alternating Chemotherapy With Intensification</i> . <i>Cancer</i> , 1985, 55, 2342-2347.	4.1	7
111	Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): Results in both untreated and previously treated patients. <i>Medical and Pediatric Oncology</i> , 1984, 12, 17-24.	1.0	5
112	Administration of a complex chemotherapy regimen: Inpatient versus outpatient treatment. <i>Medical and Pediatric Oncology</i> , 1983, 11, 333-335.	1.0	3
113	Vindesine: A phase II study in childhood malignancies-A report for cancer and leukemia group B. <i>Medical and Pediatric Oncology</i> , 1982, 10, 35-43.	1.0	4
114	Treatment of prolymphocytic leukemia. <i>Cancer</i> , 1982, 50, 1687-1689.	4.1	17
115	Anticoagulation and high dose liver radiation. A preliminary report. <i>Cancer</i> , 1979, 43, 174-181.	4.1	25
116	Prevention of Intravascular Thrombus Formation on Plastic Catheters with Heparin-Benzalkonium Complex: in Vivo and in Vitro Studies. <i>Thrombosis and Haemostasis</i> , 1979, 41, 537-543.	3.4	0
117	Incidental discovery at radical mastectomy of inapparent Hodgkin's disease in long term survivors. <i>Cancer</i> , 1978, 42, 318-325.	4.1	6
118	High dose methotrexate with citrovorum factor in adult resistant lymphoma. <i>Cancer</i> , 1977, 40, 2823-2828.	4.1	14